Krystal Biotech, Inc.
KRYSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeKrystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United. The company carries a $10.46B market cap, placing it firmly in the large-cap category. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Market Cap
$10.46B
Beta
0.50
P/E (TTM)
47.38
P/E (Fwd)
35.44
EPS (TTM)
$7.49
EPS (Fwd)
$10.01
ROE
19.9%
ROA
9.0%
Cash
$823.4M
Total Debt
$9.1M
Free CF
$137.5M
52W Change
140.6%
Annual Financials
Cash vs Debt
With $823.4M in cash and $9.1M in debt, KRYS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $137.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 19.9%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 9.0% suggests reasonable efficiency in deploying the company's asset base.
KRYS's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, KRYS has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing KRYS.